Ocular Therapeutix
OCUL
196 hedge funds and large institutions have $1.01B invested in Ocular Therapeutix in 2025 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 59 increasing their positions, 58 reducing their positions, and 16 closing their positions.
138% more call options, than puts
Call options by funds: $5.14M | Put options by funds: $2.16M
113% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 16
9% more funds holding
Funds holding: 179 → 196 (+17)
1.25% more ownership
Funds ownership: 85.13% → 86.38% (+1.2%)
2% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 58
9% less funds holding in top 10
Funds holding in top 10: 11 → 10 (-1)
12% less capital invested
Capital invested by funds: $1.14B → $1.01B (-$136M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$12.3M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$11.2M |
| 3 |
PBA
Paradigm Biocapital Advisors
New York
|
+$10.1M |
| 4 |
PCM
Peregrine Capital Management
Minneapolis,
Minnesota
|
+$6.51M |
| 5 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$4.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$21.1M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$9.22M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$7.64M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.94M |
| 5 |
Millennium Management
New York
|
-$3.82M |
OCUL Hedge Fund Activity: Q1 2025 in Review
196 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q1 2025, worth a combined $1.01B — down 12% from $1.14B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new OCUL positions and 16 closed out — a net gain of 18 holders — while 59 added to existing stakes and 58 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $12.3M. The largest seller was Opaleye Management, cutting an estimated $21.1M.
- 196 institutional investors held Ocular Therapeutix (OCUL) as of Q1 2025, up from 179 in Q4 2024.
- Funds reported $1.01B of Ocular Therapeutix stock for Q1 2025, down 12% quarter-over-quarter.
- 34 funds opened new Ocular Therapeutix positions in Q1 2025 and 16 closed out, a net change of +18 holders.
- The largest Ocular Therapeutix buyer in Q1 2025 was Adage Capital Partners, an estimated $12.3M added.
- The largest Ocular Therapeutix seller in Q1 2025 was Opaleye Management, an estimated $21.1M sold.
Based on aggregated 13F filings for Q1 2025.